19-Apr-2024
What's Going On With Novavax Stock Today?
Benzinga (Mon, 15-Apr 9:14 AM ET)
Shah Capital calls for board shake-up at Novavax
Seeking Alpha News (Mon, 15-Apr 7:48 AM ET)
Shah Capital nominates two highly qualified independent director candidates for Novavax
Globe Newswire (Mon, 15-Apr 6:00 AM ET)
Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor Push
TipRanks (Mon, 15-Apr 5:48 AM ET)
PRNewswire (Mon, 1-Apr 8:00 AM ET)
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
PRNewswire (Thu, 29-Feb 4:02 PM ET)
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
PRNewswire (Wed, 28-Feb 8:00 AM ET)
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
PRNewswire (Thu, 22-Feb 6:00 AM ET)
PRNewswire (Tue, 20-Feb 9:25 AM ET)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Novavax trades on the NASDAQ stock market under the symbol NVAX.
As of April 19, 2024, NVAX stock price climbed to $3.97 with 2,802,245 million shares trading.
NVAX has a beta of 1.36, meaning it tends to be more sensitive to market movements. NVAX has a correlation of 0.07 to the broad based SPY ETF.
NVAX has a market cap of $471.60 million. This is considered a Small Cap stock.
Last quarter Novavax reported $291 million in Revenue and -$1.47 earnings per share. This fell short of revenue expectation by $-30 million and missed earnings estimates by -$1.02.
In the last 3 years, NVAX stock traded as high as $277.80 and as low as $3.53.
The top ETF exchange traded funds that NVAX belongs to (by Net Assets): XBI, VTI, VB, IWM, VXF.
NVAX has underperformed the market in the last year with a price return of -55.7% while the SPY ETF gained +21.2%. NVAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.0% and -10.2%, respectively, while the SPY returned +3.0% and -4.5%, respectively.
NVAX support price is $3.75 and resistance is $4.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVAX stock will trade within this expected range on the day.